» Articles » PMID: 28535947

Geoepidemiology, Clinical Manifestations and Outcome of Primary Biliary Cholangitis in Greece

Overview
Specialty General Medicine
Date 2017 May 25
PMID 28535947
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Background & Aims: Primary biliary cholangitis (PBC) is a disease with rising prevalence and considerable geographical variation. To describe the prevalence, spatial and time distribution, baseline characteristics, response to treatment, outcome and the validity of GLOBE score in a large cohort of Greek PBC patients as an independent validation of this score has not been done so far.

Methods: The last 16years, 482 PBC patients (86.5% females) were evaluated and analysed retrospectively, using a prospectively collected database. Special attention was paid to the assessment of treatment response according to GLOBE score.

Results: Age at initial evaluation was 56.3±13.7years. Among 432 Thessaly residents, prevalence was 582/million (non-homogeneous distribution). Nineteen districts showed a prevalence >800/million. Symptomatic disease onset could be identified in 91 patients, with a significant peak during spring (P=0.03). At diagnosis, 43.6% were asymptomatic and 16.2% cirrhotic. Male sex (P=0.02), older age (P<0.001), alcohol consumption (P<0.01) and concomitant liver disease (P<0.001) were negative prognostic factors for cirrhosis. During a median [interquartile range, range] follow-up of 5.1 (7.8, 15.7) years, 62 patients died or underwent liver transplantation. Patients with GLOBE score>0.30 had significantly worse prognosis (P<0.001) with 5-, 10-, and 15-year survival rates of 84%, 50% and 42%.

Conclusions: There is increased PBC prevalence in Thessaly with remarkable geographic clustering and seasonal variability. PBC is diagnosed at early stages although males had a more advanced disease. GLOBE score applies perfectly in Greek patients and this will likely help detecting patients that may benefit from new therapies.

Citing Articles

Epidemiology of autoimmune liver disease in Korea: evidence from a nationwide real-world database.

Lim J, Kim H Orphanet J Rare Dis. 2024; 19(1):178.

PMID: 38685058 PMC: 11057181. DOI: 10.1186/s13023-024-03086-0.


Total and individual PBC-40 scores are reliable for the assessment of health-related quality of life in Greek patients with primary biliary cholangitis.

Rigopoulou E, Bakarozi M, Dimas I, Galanis K, Lygoura V, Gatselis N J Transl Int Med. 2023; 11(3):246-254.

PMID: 37818155 PMC: 10561069. DOI: 10.2478/jtim-2023-0098.


Risk Stratification in Primary Biliary Cholangitis.

Martini F, Balducci D, Mancinelli M, Buzzanca V, Fracchia E, Tarantino G J Clin Med. 2023; 12(17).

PMID: 37685780 PMC: 10488776. DOI: 10.3390/jcm12175713.


Primary biliary cholangitis: molecular pathogenesis perspectives and therapeutic potential of natural products.

Zhao Y, Wei S, Chen L, Zhou X, Ma X Front Immunol. 2023; 14:1164202.

PMID: 37457696 PMC: 10349375. DOI: 10.3389/fimmu.2023.1164202.


Sex-Dependent Differences in Cholestasis: Why Estrogen Signaling May Be a Key Pathophysiological Driver.

Ismail A, Kennedy L, Francis H Am J Pathol. 2023; 193(10):1355-1362.

PMID: 37422150 PMC: 10548272. DOI: 10.1016/j.ajpath.2023.06.010.